Introduction to Thyroid Imaging – Comprehensive Study Notes

Role of Imaging in Thyroid Disease

Imaging is used to correlate structural and functional information with clinical and biochemical data so that clinicians can decide whether a thyroid gland is normal, hyper- or hypofunctioning, enlarged, inflamed, infiltrated by nodules, or harbouring malignancy. After mastering the content of this lecture you should be able to articulate why imaging is ordered, select an appropriate modality in typical scenarios, and interpret a handful of signature appearances that point toward Graves’ disease, thyroiditis, a toxic nodule, multinodular goitre or a suspicious mass. You will also recognise when no imaging is necessary (for example, unequivocal Graves’ disease confirmed serologically) and when a structural study such as ultrasound must follow a functional nuclear scan.

Imaging Modalities at a Glance

Two principal techniques predominate. Thyroid ultrasound depicts anatomy, nodule morphology and vascularity in real time without ionising radiation and usually takes $15\text{–}30\text{ min}$. Thyroid scintigraphy, most often performed with technetium pertechnetate $\text{TcO}_4^-$, and less commonly with $^{123}\text{I}$, produces planar images of radionuclide uptake roughly $20$ minutes after intravenous injection, allowing quantification of global or focal function. Incidental nodules are also encountered on CT and MRI obtained for unrelated reasons (for instance a chest CT for pulmonary embolism); those discoveries usually prompt targeted ultrasound or nuclear imaging once blood tests are reviewed.

Thyroid Scintigraphy in Detail

Technetium pertechnetate exploits the same sodium–iodide symporter that ferries iodine into follicular cells but, unlike iodine, the tracer is not organified, so its thyroid residence is transient and best imaged at $20\text{ min}$ post-injection. The technique excels at quantifying percentage uptake and at demonstrating diffuse hyperfunction (Graves’ disease) or autonomous nodules (toxic adenoma). Disadvantages include exposure to ionising radiation, paucity of anatomic detail, and potential false-negative studies when the patient has recently received iodine-containing drugs such as amiodarone or iodinated CT contrast, which saturate the gland.

A third isotope, $^{131}\text{I}$, appears mainly in the treatment arena; its higher-energy β-emission ablates thyroid tissue or residual carcinoma and only small γ-emission is used for post-therapy imaging.

Ultrasound of the Thyroid

High-frequency probes render the thyroid and adjacent neck structures in exquisite detail, permitting measurement of lobe volumes, characterisation of nodules, assessment of vascular flow with Doppler and safe, real-time guidance for fine-needle aspiration cytology. Ultrasound has no radiation burden and is rapid, but it offers almost no direct information about gland function beyond a qualitative hyper- or hypovascular impression.

Imaging Hyperthyroidism

When biochemical hyperthyroidism is accompanied by a non-suppressed TSH, clinicians pursue central causes such as a pituitary adenoma. Far more commonly TSH is low; antibody testing then discriminates autoimmune Graves’ disease from other causes. If serology is diagnostic, imaging can be omitted, yet scintigraphy often remains first-line to confirm physiology and gauge suitability for radio-iodine therapy. Ultrasound subsequently clarifies any structural abnormality discovered on the nuclear scan.

A normal scintigraphic study shows faint body outline, physiologic salivary uptake and a symmetric, butterfly-shaped gland. In Graves’ disease the gland is enlarged, demonstrates uniform, intense tracer accumulation and eclipses background soft-tissue uptake; quantitative uptake can be markedly elevated, for example $12.5\%$ versus an upper reference of $3.5\%$. Duplex ultrasound corroborates an enlarged, hypoechoic gland that blazes with hypervascular “thyroid inferno”.

Subacute (de Quervain) thyroiditis produces the opposite picture: clinically hyperthyroid yet globally diminished uptake because the inflamed gland has already discharged hormonal stores and is now unwilling to trap tracer. Ultrasound shows a patchy, heterogeneous and relatively avascular thyroid.

Multinodular goitre leads to scintigraphic heterogeneity: patches of hot and cold activity within an enlarged outline. Cold or hypofunctioning areas bear higher malignant potential and warrant targeted ultrasound evaluation. Sonography demonstrates a bulky, lobulated gland packed with nodules of mixed echogenicity; giant goitres may descend retrosternally.

An autonomous (toxic) adenoma presents as a single, focal region of markedly increased uptake with suppression of the remainder of the thyroid. Such hyperfunctioning nodules are almost always benign.

Hashimoto thyroiditis, typically an autoimmune hypothyroid process, may share the heterogeneous echotexture of subacute thyroiditis but usually retains normal or reduced blood flow and, if early, may be diffusely enlarged with scattered hypoechoic micronodules.

Assessment of Thyroid Nodules

Ultrasound surveys reveal nodules in $50\text{–}68\%$ of adults, yet fewer than $5\%$ prove malignant. Papillary carcinoma is the dominant histology and often indolent. Widespread screening programs increased diagnosis rates without altering mortality, prompting an international effort to curtail unnecessary biopsy and thyroidectomy. Comprehensive risk-stratification systems emerged, notably ACR TI-RADS, which scores nodules according to composition, echogenicity, shape, margin characteristics and intralesional echogenic foci or calcification. The composite score guides evidence-based recommendations: ignore, surveil or biopsy.

In TI-RADS the observer notes whether a lesion is solid, cystic, spongiform, iso-, hypo- or markedly hypoechoic compared with normal thyroid, taller-than-wide, smoothly marginated or irregular, and whether micro- or macro-calcifications are present. Those granular details are synthesised into one of five risk tiers; you are not expected to memorise the table but should appreciate its purpose and the parameters scrutinised.

Illustrative Cases

A $35$-year-old woman with multinodular goitre displayed a $13\text{ mm}$ spongiform nodule whose multiseptated, “sea-sponge” architecture is a benign hallmark; no further action was necessary.

A distinct nodule measuring $2.3\text{ cm}$ showed numerous punctate echogenic foci, coarse macro-calcification with acoustic shadowing and irregular borders. Fine-needle aspiration confirmed papillary thyroid carcinoma.

A third solid, markedly hypoechoic nodule with peripheral and internal vascularity and a jagged outline also underwent biopsy and revealed follicular thyroid carcinoma, underscoring that vascular, very dark, irregular nodules merit cytologic evaluation.

Radioactive Iodine Therapy ((^{131}\text{I}))

Therapeutic iodine $^{131}\text{I}$, administered orally, emits high-energy β-particles that ablate functioning thyroid tissue while its γ-photons permit post-treatment imaging. Because well-differentiated thyroid cancers and their nodal or distant metastases often retain the sodium–iodide symporter, they avidly concentrate $^{131}\text{I}$ and receive lesion-directed radiotherapy. The same approach treats refractory hyperthyroidism in Graves’ disease or in patients with toxic nodules. Once the capsule is ingested, organification locks the isotope within the follicular cells, delivering cytotoxic dose to both primary and metastatic foci.

Practical and Ethical Implications

Clinicians must weigh the modest radiation dose of diagnostic scintigraphy against the value of knowing whether hyperthyroidism is diffuse or focal, as that answer steers medical, surgical or radio-iodine management. Ultrasound offers a radiation-free map for surveillance and biopsy but, if over-used, can prompt unwarranted surgery for indolent cancers. The modern emphasis is therefore on coupling high-quality imaging with evidence-based triage systems (such as TI-RADS) to curb over-diagnosis and mitigate the lifelong morbidity of thyroidectomy and hormone replacement.

By integrating biochemistry, clinical presentation and the complementary strengths of ultrasound and scintigraphy, clinicians achieve a nuanced, patient-centred pathway that diagnoses clinically meaningful disease, avoids futile interventions and mobilises targeted radioactive iodine when cure or palliation is feasible.